<DOC>
	<DOCNO>NCT00384462</DOCNO>
	<brief_summary>The purpose study describe respiratory syncytial virus ( RSV ) hospitalization rate begin address utilization outpatient resource RSV medically-attended low respiratory tract infection ( MALRI ) 32-35 week gestational age ( GA ) premature infant less 6 month age receive treatment .</brief_summary>
	<brief_title>Study Evaluate Incidence Hospitalizations Respiratory Tract Infections Premature Infants</brief_title>
	<detailed_description>The goal study : - To estimate incidence hospitalization attributable RSV within 150 day enrollment premature infant : - 32-35 week GA - less 6 month age start RSV season - receiving palivizumab prophylaxis recommend receive palivizumab accord AAP guideline - To estimate incidence rate hospitalization attributable RSV relevant study population time period ( e.g. , Cohort 2 , Cohorts 1 2 combine , subgroup base chronological age start RSV season , GA , etc . within 150 day enrollment time period base RSV activity , etc . ) - To estimate incidence RSV-associated MALRI study population - To characterize incidence type clinical intervention MALRI study population</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Parent/legal guardian able understand provide write informed consent Male female infant born 3235 week GA. GA determine accord available medical record . Clinically stable , opinion investigator Ability willingness subject 's parent/legal guardian complete protocol mandate followup telephone call , visit procedure Not one follow American Academy Pediatrics ( AAP ) define risk factor : 1 . Childcare attendance 2 . Schoolaged sibling home 3 . Exposure environmental air pollutant ( include passive exposure tobacco smoke ) 4 . Congenital abnormality airways 5 . Severe neuromuscular disease , determine investigator Subject must meet criterion list either Cohort 1 Cohort 2 : Cohort 1 Date enrollment 01/Oct 15/Dec Chronological age &lt; 6 month ( i.e. , yet reach 6month birthday ) traditional start local RSV season ( use determine eligibility RSV prophylaxis ) Cohort 2 Date enrollment 16/Dec 15/Feb Born current RSV season discharge hospital nursery 01/Dec Previous ( within 90 day enrollment ) concurrent treatment palivizumab RSVIGIV IVIG Hospitalization time enrollment ( unless discharge anticipate within 10 day ) Two AAPdefined risk factor list Inclusion Criteria Participation trial investigational RSV prophylaxis therapeutic agent Confirmed prior current RSV infection ( child current signs/symptoms respiratory infection must negative RSV test ) Diagnosis chronic lung disease ( CLD ) prematurity ( formerly refer bronchopulmonary dysplasia [ BPD ] ) Diagnosis hemodynamically significant congenital heart disease ( CHD ) , define require medication supplemental oxygen CHD Known immunodeficiency Life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Premature infant ( 32-35 week GA ) &lt; 6 month age start RSV season receive palivizumab CLD prematurity</keyword>
	<keyword>Respiratory Syncytial Viruses</keyword>
</DOC>